Cross Staff Investments’s Advanced Micro Devices AMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.83M Hold
3,154
1.03% 21
2026
Q1
$642K Hold
3,154
0.33% 65
2025
Q4
$675K Hold
3,154
0.37% 63
2025
Q3
$510K Hold
3,154
0.36% 76
2025
Q2
$448K Sell
3,154
-1,478
-32% -$161K 0.33% 82
2025
Q1
$476K Hold
4,632
0.36% 74
2024
Q4
$559K Sell
4,632
-350
-7% -$50.4K 0.39% 64
2024
Q3
$817K Sell
4,982
-500
-9% -$76K 0.63% 43
2024
Q2
$889K Sell
5,482
-272
-5% -$43.8K 0.74% 39
2024
Q1
$1.04M Hold
5,754
0.87% 36
2023
Q4
$848K Sell
5,754
-100
-2% -$11.8K 0.75% 39
2023
Q3
$602K Sell
5,854
-100
-2% -$10.9K 0.59% 49
2023
Q2
$678K Buy
5,954
+200
+3% +$20.8K 0.62% 47
2023
Q1
$564K Buy
5,754
+650
+13% +$52.9K 0.56% 54
2022
Q4
$331K Sell
5,104
-2,790
-35% -$184K 0.35% 91
2022
Q3
$500K Sell
7,894
-2,900
-27% -$247K 0.56% 51
2022
Q2
$825K Buy
10,794
+271
+3% +$25.4K 0.91% 31
2022
Q1
$1.15M Buy
10,523
+200
+2% +$23.9K 1.07% 27
2021
Q4
$1.49M Buy
+10,323
New +$1.39M 1.33% 16

Other funds holding AMD

Cross Staff Investments's AMD Position: Q2 2026 in Review

Cross Staff Investments held its Advanced Micro Devices (AMD) position steady in Q2 2026 at 3,154 shares worth $1.83M. The position accounts for 1.03% of the portfolio, ranked #21.

Cross Staff Investments first reported a position in AMD in Q4 2021 and has held it in 19 quarters since. 1,865 funds tracked by Wall St. Rank hold AMD as of Q2 2026.

  • Cross Staff Investments held 3,154 shares of Advanced Micro Devices worth $1.83M as of Q2 2026.
  • Cross Staff Investments left its Advanced Micro Devices share count unchanged in Q2 2026.
  • Advanced Micro Devices made up 1.03% of Cross Staff Investments's portfolio in Q2 2026, its #21 holding.
  • Cross Staff Investments first reported a position in Advanced Micro Devices in Q4 2021 and has held it in 19 quarters since.
  • 1,865 funds tracked by Wall St. Rank held Advanced Micro Devices as of Q2 2026.

Based on Cross Staff Investments's 13F filing for Q2 2026, filed 22 Jul 2026.